Lecimibide | CAS#130804-35-2 | Antihyperlipidemic

MedKoo Cat#: 598537 | Name: Lecimibide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Lecimibide is an antihyperlipidemic drug.

Chemical Structure

Lecimibide

CAS#130804-35-2

Theoretical Analysis

MedKoo Cat#: 598537

Name: Lecimibide

CAS#: 130804-35-2

Chemical Formula: C34H40F2N4OS

Exact Mass: 590.2891

Molecular Weight: 590.77

Elemental Analysis: C, 69.12; H, 6.82; F, 6.43; N, 9.48; O, 2.71; S, 5.43

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Lecimibide; DuP 128; DuP-128; DuP128;

IUPAC/Chemical Name

3-(2,4-difluorophenyl)-1-(5-((4,5-diphenyl-1H-imidazol-2-yl)thio)pentyl)-1-heptylurea

InChi Key

TVXOXGBTADZYCZ-UHFFFAOYSA-N

InChi Code

InChI=1S/C34H40F2N4OS/c1-2-3-4-5-13-22-40(34(41)37-30-21-20-28(35)25-29(30)36)23-14-8-15-24-42-33-38-31(26-16-9-6-10-17-26)32(39-33)27-18-11-7-12-19-27/h6-7,9-12,16-21,25H,2-5,8,13-15,22-24H2,1H3,(H,37,41)(H,38,39)

SMILES Code

O=C(NC1=CC=C(F)C=C1F)N(CCCCCSC2=NC(C3=CC=CC=C3)=C(C4=CC=CC=C4)N2)CCCCCCC

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 590.77 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Sliskovic DR, Krause BR, Picard JA, Anderson M, Bousley RF, Hamelehle KL, Homan R, Julian TN, Rashidbaigi ZA, Stanfield RL. Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. 6. The first water-soluble ACAT inhibitor with lipid-regulating activity. J Med Chem. 1994 Mar 4;37(5):560-2. PubMed PMID: 8126693. 2: Harte RA, Yeaman SJ, Jackson B, Suckling KE. Effect of membrane environment on inhibition of acyl-CoA:cholesterol acyltransferase by a range of synthetic inhibitors. Biochim Biophys Acta. 1995 Oct 5;1258(3):241-50. PubMed PMID: 7548193. 3: Hainer JW, Terry JG, Connell JM, Zyruk H, Jenkins RM, Shand DL, Gillies PJ, Livak KJ, Hunt TL, Crouse JR 3rd. Effect of the acyl-CoA:cholesterol acyltransferase inhibitor DuP 128 on cholesterol absorption and serum cholesterol in humans. Clin Pharmacol Ther. 1994 Jul;56(1):65-74. PubMed PMID: 8033496. 4: Miyazaki A, Horiuchi S. [ACAT inhibitors]. Nihon Rinsho. 2001 Mar;59 Suppl 3:675-80. Review. Japanese. PubMed PMID: 11347152. 5: Brown WJ, Schmidt JA. Use of acyltransferase inhibitors to block vesicular traffic between the ER and Golgi complex. Methods Enzymol. 2005;404:115-25. PubMed PMID: 16413263. 6: Hoang VQ, Botham KM, Pearce NJ, Suckling KE. The regulation of bile acid synthesis in cultured hamster hepatocytes. Biochem Soc Trans. 1993 Aug;21 ( Pt 3)(3):284S. PubMed PMID: 8224434. 7: Huff MW, Telford DE, Barrett PH, Billheimer JT, Gillies PJ. Inhibition of hepatic ACAT decreases ApoB secretion in miniature pigs fed a cholesterol-free diet. Arterioscler Thromb. 1994 Sep;14(9):1498-508. PubMed PMID: 8068612. 8: Harte RA, Jackson B, Suckling KE, Yeaman SJ. Differences in the potency of ACAT inhibitors in two assay systems. Biochem Soc Trans. 1993 Aug;21 ( Pt 3)(3):325S. PubMed PMID: 8224469. 9: Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Barrett PH, Huff MW. Inhibition of cholesterol esterification by DuP 128 decreases hepatic apolipoprotein B secretion in vivo: effect of dietary fat and cholesterol. Biochim Biophys Acta. 1998 Jul 31;1393(1):63-79. PubMed PMID: 9714740. 10: Higley CA, Wilde RG, Maduskuie TP, Johnson AL, Pennev P, Billheimer JT, Robinson CS, Gillies PJ, Wexler RR. Acyl CoA:cholesterol acyltransferase (ACAT) inhibitors: synthesis and structure-activity relationship studies of a new series of trisubstituted imidazoles. J Med Chem. 1994 Oct 14;37(21):3511-22. PubMed PMID: 7932580. 11: Hernandez M, Montenegro J, Steiner M, Kim D, Sparrow C, Detmers PA, Wright SD, Chao YS. Intestinal absorption of cholesterol is mediated by a saturable, inhibitable transporter. Biochim Biophys Acta. 2000 Jul 19;1486(2-3):232-42. PubMed PMID: 10903474. 12: Lai CM, Brogdon B, Quon CY, Pieniaszek HJ Jr. Determination of DuP 128, an ACAT inhibitor and its sulphoxide and sulphone metabolites in human plasma by liquid chromatography. J Pharm Biomed Anal. 1994 Sep;12(9):1163-72. PubMed PMID: 7803568.